Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01652365
Other study ID # 19371-106
Secondary ID HS805
Status Completed
Phase N/A
First received July 24, 2012
Last updated July 27, 2012
Start date March 2011
Est. completion date June 2012

Study information

Verified date July 2012
Source Harvard School of Public Health
Contact n/a
Is FDA regulated No
Health authority United States: Harvard School of Public Health Office of Regulatory Affairs and Research ComplianceUganda: Uganda National Council for Science and Technology
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the feasibility and impact of introducing subsidized malaria rapid diagnostic tests (RDTs) into retail sector drug shops in Uganda. This is a randomized controlled trial at the village level, taking place in 6 districts in Eastern Uganda. Licensed drug shops in selected villages were trained in proper RDT storage, administration, interpretation and disposal and were given access to subsidized RDTs for sale. This study explores whether drug shop owners--when given access to training and subsidized RDTs--will choose to promote and sell RDTs to customers and, if so, at what volume and what price. The investigators also explore whether shops will safely store, administer, interpret and dispose of RDTs and to what extent they will use RDT results to guide treatment recommendations. Finally, the study explores whether making RDTs available for sale in local drug shops has a community level impact on diagnostic testing and appropriate treatment for malaria.


Recruitment information / eligibility

Status Completed
Enrollment 2800
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Drug Shops:

- Licensed and registered as a Drug Shop with the Ugandan National Drug Authority

Households:

- Live in the village of participating drug shop

- Female household head is 18 or over

Exclusion Criteria:

Drug Shops:

- Drug Shop not registered with Ugandan National Drug Authority

- Female household head is under 18

Study Design

Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Behavioral:
RDT Training and Subsidy Offered

Information/Education Campaign


Locations

Country Name City State
Uganda Clinton Health Access Initiative Kampala
Uganda Innovations for Poverty Action-Uganda Kampala

Sponsors (4)

Lead Sponsor Collaborator
Harvard School of Public Health Clinton Health Access Initiative, Nigeria, Innovations for Poverty Action-Uganda, Uganda Health Marketing Group

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fraction of Illnesses Diagnosed for Malaria Comparison of the rate of malaria diagnosis in treatment vs. control. Comparison will be at the village level and at the shop level. Denominator will be: all illnesses, febrile illnesses only or suspected malaria episodes only. Up To One Year No
Secondary Mean RDT Price Charged by Shops Up to One Year No
Secondary Mean RDTs Purchased by Shops from Wholesaler Up To One Year No
Secondary Fraction of Monitoring Checklist Items Performed Correctly by Shops Up To One Year No
Secondary Fraction of Illnesses for which an Antimalarial/ACT/Antibiotic is Taken Comparison of rate of antimalarial taking for illnesses in treatment vs. control
Comparison of rate of ACT taking for illnesses in treatment vs. control
Comparison of rate of antibiotic taking for illnesses in treatment vs. control
Up To One Year No
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3